We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Details Steps to Ensure Smooth Transition of IRBs
FDA Details Steps to Ensure Smooth Transition of IRBs
June 9, 2014
Institutional review boards that assume oversight of a clinical trial from another IRB should give drugmakers an opportunity to address any concerns the receiving IRB has with the study before it is terminated or suspended, an FDA final guidance says.